Pharmacokinetics of metoprolol enantiomers following single and multiple administration of racemate in rat

被引:27
作者
Mostafavi, SA [1 ]
Foster, RT [1 ]
机构
[1] Univ Alberta, Fac Pharm & Pharmaceut Sci, Edmonton, AB T6G 2N8, Canada
关键词
metoprolol; pharmacokinetics; enantiomers; single dose; multiple dose;
D O I
10.1016/S0378-5173(00)00430-0
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The chiral beta-adrenergic blocking agent metoprolol (MET), which is marketed as a racemate, is a highly extracted drug with rapid absorption. The enantiomeric disposition of MET is reported following racemic administration as a single and as multiple ol al dosing foul times per day for four days in male Sprague-Dawley rats (n=6 in each group). Plasma was collected and enantiomeric concentrations of MET were determined using a stereospecific HPLC assay. The R/S ratio for AUC is not statistically different from unity either after single or after multiple administration of racemate. The oral clearance after single dose was 1.99 +/- 0.87 and 2.26 +/- 0.85 ml min(-1) kg(-1) for R- and S-MET, respectively. These values were decreased to 0.59 +/- 0.21 and 0.64 +/- 0.26 ml min(-1) kg(-1) after multiple administration of racemate. The corresponding values for the elimination half-lives were approximately 35 and 33 min after single and multiple dose administration For both enantiomers, respectively. These results may suggest a saturable first pass metabolism of MET as its enantiomers are accumulated in plasma following multiple dosing in the rat model. (C) 2000 Published by Elsevier science B.V. All rights reserved.
引用
收藏
页码:97 / 102
页数:6
相关论文
共 19 条
[11]   THE POLYMORPHIC OXIDATION OF BETA-ADRENOCEPTOR ANTAGONISTS - CLINICAL PHARMACOKINETIC CONSIDERATIONS [J].
LENNARD, MS ;
TUCKER, GT ;
WOODS, HF .
CLINICAL PHARMACOKINETICS, 1986, 11 (01) :1-17
[12]   OXIDATION PHENOTYPE - A MAJOR DETERMINANT OF METOPROLOL METABOLISM AND RESPONSE [J].
LENNARD, MS ;
SILAS, JH ;
FREESTONE, S ;
RAMSAY, LE ;
TUCKER, GT ;
WOODS, HF .
NEW ENGLAND JOURNAL OF MEDICINE, 1982, 307 (25) :1558-1560
[13]  
Mostafavi SA, 1998, BIOPHARM DRUG DISPOS, V19, P425, DOI 10.1002/(SICI)1099-081X(199810)19:7<425::AID-BDD121>3.3.CO
[14]  
2-O
[15]   METOPROLOL KINETICS AND DOSE-RESPONSE IN HYPERTENSIVE PATIENTS [J].
MYERS, MG ;
THIESSEN, JJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1980, 27 (06) :756-762
[16]  
QUARTERMAN CP, 1993, BR J CLIN PHARM, V11, P287
[17]  
REGARDH CG, 1975, ACTA PHARMACOL TOX, V36, P45
[18]   AGING AND THE PHARMACOKINETICS AND METABOLISM OF METOPROLOL ENANTIOMERS IN THE RAT [J].
VERMEULEN, AM ;
BELPAIRE, FM ;
DESMET, F ;
VERCRUYSSE, I ;
BOGAERT, MG .
JOURNALS OF GERONTOLOGY, 1993, 48 (03) :B108-B114
[19]  
Waagstein F., 1998, European Heart Journal, V19, P307